文献速递神经肿瘤

非颅底非视周良性幕上脑膜瘤伽玛刀术后10年以上放射毒性及长期肿瘤控制的相关因素

Factors associated with radiation toxicity and long-term tumor control more than 10 years after Gamma Knife surgery for non-skull base, nonperioptic benign supratentorial meningiomas.
PubMed 文献 · J Neurosurg · 2022-10-07

该回顾性研究纳入1998至2010年间在本机构接受伽玛刀手术的非颅底非视周良性幕上脑膜瘤患者55例(68个肿瘤),随访超过10年,分析剂量学因素与长期局部控制及症状性放射不良反应的关系。多因素分析显示D98%是局部控制的显著因素(临界值11 Gy,HR 0.754,p<0.001),nV14Gy与症状性放射不良反应显著相关(临界值0.66 cm³,HR 2.459,p=0.002)。作者推荐边缘剂量11–14 Gy以实现长期疗效与安全性。

要点

  • D98%临界值11 Gy与长期局部控制显著相关(HR 0.754,p<0.001)。
  • nV14Gy临界值0.66 cm³与症状性放射不良反应显著相关(HR 2.459,p=0.002)。
  • 作者推荐边缘剂量11–14 Gy并确保肿瘤充分覆盖。

核心结论

  • D98%是长期局部控制所需最低剂量的指标,nV14Gy与症状性放射不良反应相关。
  • 作者推荐对非颅底非视周良性幕上脑膜瘤采用11–14 Gy的边缘剂量以实现长期疗效与安全性,前提是肿瘤充分覆盖。

研究设计与样本

  • 回顾性分析1998至2010年间在本机构接受伽玛刀手术治疗上述部位良性脑膜瘤且随访超过10年的患者。
  • 使用剂量-体积直方图提取剂量学因素,采用Cox比例风险回归分析局部控制和放射不良反应的相关因素。

主要发现

  • 共纳入55例患者(男/女比例1:4.2),68个肿瘤;中位(范围) gross target volume为4.2(0.2–31.7)cm³,中位边缘剂量为14.3(9–20)Gy。
  • 23.5%的肿瘤进展,平均进展时间72个月;10年和15年无进展生存率分别为80.9%和73.5%。
  • 单因素分析中,较高的边缘剂量、覆盖率(%)、Dmin、D98%、Dmean、D2%、Dmax和Paddick适形指数与局部控制显著相关。
  • 多因素分析中D98%为显著因素,临界值11 Gy(HR 0.754,p<0.001)。
  • 7例患者出现症状性放射不良反应,平均出现时间伽玛刀术后7个月;放射不良反应与接受超过14 Gy照射的正常组织体积(nV14Gy)显著相关,临界值0.66 cm³(HR 2.459,p=0.002)。

关键数值与推荐

  • D98%临界值11 Gy(HR 0.754,p<0.001)与长期局部控制相关。
  • nV14Gy临界值0.66 cm³(HR 2.459,p=0.002)与症状性放射不良反应相关。
  • 作者推荐边缘剂量11–14 Gy,并假设肿瘤充分覆盖。

临床怎么用

  • 作者推荐对非颅底非视周良性幕上脑膜瘤采用11–14 Gy的边缘剂量以实现长期疗效与安全性,前提是肿瘤充分覆盖。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Gamma Knife surgery (GKS) is a well-established treatment for benign intracranial meningiomas; however, the dosimetric factors associated with long-term GKS efficacy and safety remain to be elucidated. Using data obtained with at least 10 years of follow-up, the authors aimed 1) to analyze GKS efficacy and safety for the treatment of benign meningiomas confined to non-skull base, nonperioptic supratentorial locations and 2) to determine the radiation dose window that allows for long-term efficacy and safety, namely the minimum dose to achieve long-term local control (LC) and the maximum safe dose to avoid adverse radiation effects (AREs). METHODS: A retrospective analysis was performed on patients who underwent GKS for benign meningiomas in the abovementioned location at the authors' institution between 1998 and 2010 and who received follow-up for more than 10 years. The authors meticulously extracted the values of various dosimetric factors by using a dose-volume histogram. Cox proportional hazard regression analyses were performed to investigate the dosimetric factors associated with LC and ARE. RESULTS: Fifty-five patients (male/female ratio 1:4.2) with 68 tumors were enrolled. The median (range) gross target volume and marginal dose were 4.2 (0.2-31.7) cm3 and 14.3 (9-20) Gy, respectively. In total, 23.5% of tumors progressed at an average of 72 months, with 10- and 15-year progression-free survival rates of 80.9% and 73.5%, respectively. In univariate analysis, higher marginal dose, coverage (%), Dmin, D98%, Dmean, D2%, Dmax, and Paddick conformity index were significantly associated with LC. In multivariate analysis, D98% was the significant factor, with a cutoff value of 11 Gy (HR 0.754, p < 0.001). Symptomatic AREs occurred in 7 patients at an average of 7 months after GKS. AREs were significantly associated with the volume of normal tissue irradiated with more than 14 Gy (nV14Gy), with a cutoff value of 0.66 cm3 (HR 2.459, p = 0.002). CONCLUSIONS: D98% was a barometer of the minimum required dose associated with long-term LC, and nV14Gy was related to symptomatic AREs. The authors recommend a marginal dose ranging from 11 to 14 Gy to achieve long-term efficacy and safety in patients with non-skull base, nonperioptic benign supratentorial meningiomas, with the assumption of thorough tumor coverage.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Lee EJ, Chung HT, Park H, et al. Factors associated with radiation toxicity and long-term tumor control more than 10 years after Gamma Knife surgery for non-skull base, nonperioptic benign supratentorial meningiomas. J Neurosurg. 2022. PMID: 36208439. doi:10.3171/2022.8.JNS22422

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。